Targeted drug shows promise for Hard-to-Treat kidney cancer
NCT ID NCT03786796
First seen Apr 16, 2026 · Last updated May 15, 2026 · Updated 3 times
Summary
This study tests a daily pill called olaparib in people with advanced kidney cancer that has certain gene mutations (like BAP-1 or BRCA). The goal is to see if the drug can shrink tumors or keep them stable for at least six months. About 20 adults who have already tried other treatments will take part. The drug works by blocking a repair process that cancer cells rely on.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
RECRUITINGBaltimore, Maryland, 21228, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.